Targacept Inc.
This article was originally published in Start Up
Executive Summary
Targacept spun out in 2000 from tobacco giant RJ Reynolds, with 60 patents, 23 scientists and an ongoing strategic alliance with Aventis. Not to mention $30 million from venture backers excited about the company's potential for discovering drugs that act on neuronal nicotinic receptors.
You may also be interested in...
One Company's Distraction Is Another's Lead Product
Hoping to unfreeze investor attitudes toward the industry, biotechs are embracing product strategies with the enthusiasm of religious converts. Platforms are out; so, increasingly, is discovery. The clinic is in. Targacept and Layton Bioscience are both embracing this philosophy, which enabled their deal in which Targacept bought rights to a marketed small-molecule from cell therapist Layton.
Tranzyme Inc.
The founders of Tranzyme Inc. believe that since HIV can infect and transfer its DNA into a wide range of cell types, by rendering the virus pathologically ineffective, they could turn the virus into an effective delivery system for gene therapy.
Tranzyme Inc.
The founders of Tranzyme Inc. believe that since HIV can infect and transfer its DNA into a wide range of cell types, by rendering the virus pathologically ineffective, they could turn the virus into an effective delivery system for gene therapy.